Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout Post published:June 28, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedule I Placement for DOI and DOC Post published:June 27, 2025 Post category:Psychedelic Bulletin/Pα+
Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results Post published:June 25, 2025 Post category:Analysis/News/Pα+
Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle Post published:June 23, 2025 Post category:Analysis/News
Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program Post published:June 18, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile Post published:June 13, 2025 Post category:Psychedelic Bulletin/Pα+
May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape Post published:June 12, 2025 Post category:Psychedelic Patent Analysis/Pα+
Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class of Bulletin #100 Post published:June 6, 2025 Post category:Psychedelic Bulletin
The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access Post published:June 4, 2025 Post category:Op-ed
Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers Post published:June 2, 2025 Post category:Analysis/News/Pα+